BR112021022404A2 - Composições de oximetazolina e métodos para tratamento de distúrbios oculares - Google Patents

Composições de oximetazolina e métodos para tratamento de distúrbios oculares

Info

Publication number
BR112021022404A2
BR112021022404A2 BR112021022404A BR112021022404A BR112021022404A2 BR 112021022404 A2 BR112021022404 A2 BR 112021022404A2 BR 112021022404 A BR112021022404 A BR 112021022404A BR 112021022404 A BR112021022404 A BR 112021022404A BR 112021022404 A2 BR112021022404 A2 BR 112021022404A2
Authority
BR
Brazil
Prior art keywords
oxymetazoline
compositions
methods
eye disorders
treating eye
Prior art date
Application number
BR112021022404A
Other languages
English (en)
Portuguese (pt)
Inventor
David Jacobs
Tina Devries
Original Assignee
Rvl Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rvl Pharmaceuticals Inc filed Critical Rvl Pharmaceuticals Inc
Publication of BR112021022404A2 publication Critical patent/BR112021022404A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112021022404A 2019-05-06 2020-05-05 Composições de oximetazolina e métodos para tratamento de distúrbios oculares BR112021022404A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962844069P 2019-05-06 2019-05-06
US201962843819P 2019-05-06 2019-05-06
US16/716,014 US10799481B1 (en) 2019-05-06 2019-12-16 Compositions and methods for treating ocular disorders
US16/715,998 US10814001B1 (en) 2019-05-06 2019-12-16 Oxymetazoline compositions
PCT/US2020/031425 WO2020227260A1 (en) 2019-05-06 2020-05-05 Oxymetazoline compositions and methods for treating ocular disorders

Publications (1)

Publication Number Publication Date
BR112021022404A2 true BR112021022404A2 (pt) 2022-01-18

Family

ID=72750169

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022404A BR112021022404A2 (pt) 2019-05-06 2020-05-05 Composições de oximetazolina e métodos para tratamento de distúrbios oculares

Country Status (16)

Country Link
US (11) US10814001B1 (https=)
EP (1) EP3965737A1 (https=)
JP (3) JP7141420B2 (https=)
KR (3) KR102410503B1 (https=)
CN (2) CN111888326B (https=)
AU (1) AU2020268329B2 (https=)
BR (1) BR112021022404A2 (https=)
CL (1) CL2021002918A1 (https=)
CO (1) CO2021015265A2 (https=)
IL (1) IL287831A (https=)
MA (1) MA55895A (https=)
MX (1) MX2021013516A (https=)
PE (1) PE20220384A1 (https=)
SG (1) SG11202112272TA (https=)
WO (1) WO2020227260A1 (https=)
ZA (2) ZA202108950B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
US10814001B1 (en) * 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
WO2022187306A1 (en) 2021-03-03 2022-09-09 Voom, Llc Compositions and methods for treatment of blepharitis
WO2023079427A1 (en) * 2021-11-03 2023-05-11 Avaca Pharma Private Limited Ophthalmic compositions and methods thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE51421B1 (en) 1980-08-01 1986-12-24 Smith & Nephew Ass Ophthalmic compositions containing triamterene
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5888493A (en) 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
JP2002249445A (ja) 2000-12-19 2002-09-06 Ophtecs Corp 眼科用液剤組成物
US6806364B2 (en) 2002-07-29 2004-10-19 Ast Products, Inc. Ophthalmic compositions
CN101327325A (zh) * 2002-07-30 2008-12-24 奥默罗斯公司 眼科冲洗液及方法
DE10337186A1 (de) 2003-08-13 2005-03-17 Merck Patent Gmbh Wässrige Wirkstoff-Lösung
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
JP2006131628A (ja) * 2004-10-08 2006-05-25 Rohto Pharmaceut Co Ltd オキシメタゾリン含有水性組成物
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
AU2007227091B2 (en) 2006-03-17 2013-02-07 Johnson & Johnson Vision Care, Inc. Stabilized ophthalmic compositions comprising oxidatively unstable components
CA2650592A1 (en) 2006-04-26 2007-11-08 Aciex, Inc. Compositions for the treatment and prevention of eyelid swelling
WO2008070185A2 (en) * 2006-12-06 2008-06-12 The Trustees Of Columbia University In The City Of New York Method of stabilizing human eye tissue by reaction with nitrite and related agents such as nitro compounds
WO2009061431A2 (en) 2007-11-08 2009-05-14 Aciex Therapeutics, Inc. Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
BRPI0821647A2 (pt) 2007-12-21 2015-06-16 Schering Plough Healthcare Realce da fotosestabillização de oximetazolina
JP5581227B2 (ja) * 2008-03-11 2014-08-27 アルコン リサーチ， リミテッド 硝子体内注射のための低粘度、高凝集トリアムシノロンアセトニド懸濁剤
WO2010141831A1 (en) * 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations, methods of manufacture, and methods of using same
US20120082625A1 (en) 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
AU2011327785A1 (en) * 2010-11-08 2013-03-07 Healor Ltd. Buffered ophthalmic compositions and methods of use thereof
US8883838B2 (en) 2010-12-03 2014-11-11 Allergan, Inc. Pharmaceutical cream compositions and methods of use
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
CA2833420C (en) 2011-04-26 2019-09-03 Rdd Pharma Ltd. Oxymetazoline for the treatment of ano-rectal disorders
JP2015518006A (ja) 2012-05-25 2015-06-25 エクスクリア インコーポレイテッド キシリトール系の抗粘膜組成物及び関連する方法並びに組成物
UA119324C2 (uk) 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
CN106034406B (zh) 2013-09-18 2019-09-10 迈康尼股份公司 对smt系统操作员提供信息的方法、系统和设备
AU2015274532B2 (en) 2014-06-11 2020-06-11 Epi Health, Llc Stabilized oxymetazoline formulations and their uses
EP3302426A4 (en) 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
US20170312335A1 (en) * 2015-12-30 2017-11-02 Lubris Llc Topical use of prg4 for treatment of allergy and symptoms of inflammation
CN108883308A (zh) 2016-01-26 2018-11-23 利维申制药有限公司 α-肾上腺素能药剂的组合物和用途
CN105997856A (zh) * 2016-06-24 2016-10-12 魏威 盐酸羟甲唑啉滴眼液及其制备方法
US11246816B2 (en) 2016-06-30 2022-02-15 The Procter And Gamble Company Shampoo compositions comprising a chelant
US10814001B1 (en) * 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions

Also Published As

Publication number Publication date
US20230355587A1 (en) 2023-11-09
CL2021002918A1 (es) 2022-08-19
US20210386711A1 (en) 2021-12-16
US10898573B1 (en) 2021-01-26
KR20200128629A (ko) 2020-11-16
CN111888326B (zh) 2023-07-21
US11701343B2 (en) 2023-07-18
KR102663319B1 (ko) 2024-05-03
US20240033250A1 (en) 2024-02-01
US11103482B2 (en) 2021-08-31
US11541036B2 (en) 2023-01-03
US11324722B2 (en) 2022-05-10
US20210212992A1 (en) 2021-07-15
EP3965737A1 (en) 2022-03-16
SG11202112272TA (en) 2021-12-30
ZA202108950B (en) 2023-10-25
CN117045596A (zh) 2023-11-14
AU2020268329B2 (en) 2026-01-15
JP7141420B2 (ja) 2022-09-22
KR102859351B1 (ko) 2025-09-12
IL287831A (en) 2022-01-01
US20220273621A1 (en) 2022-09-01
CA3139443A1 (en) 2020-11-12
US20210137889A1 (en) 2021-05-13
KR102410503B1 (ko) 2022-06-17
NZ782902A (en) 2024-09-27
WO2020227260A1 (en) 2020-11-12
US20220257566A1 (en) 2022-08-18
US11311515B2 (en) 2022-04-26
JP2021191802A (ja) 2021-12-16
MX2021013516A (es) 2022-01-24
JP7705326B2 (ja) 2025-07-09
KR20240060580A (ko) 2024-05-08
AU2020268329A1 (en) 2022-01-06
PE20220384A1 (es) 2022-03-18
US20200353083A1 (en) 2020-11-12
ZA202212328B (en) 2025-03-26
US12605363B2 (en) 2026-04-21
US20210015795A1 (en) 2021-01-21
KR20220084264A (ko) 2022-06-21
US10940138B2 (en) 2021-03-09
US10799481B1 (en) 2020-10-13
CO2021015265A2 (es) 2022-02-28
JP2020183373A (ja) 2020-11-12
US20210023222A1 (en) 2021-01-28
JP2025065198A (ja) 2025-04-17
US10814001B1 (en) 2020-10-27
CN111888326A (zh) 2020-11-06
MA55895A (fr) 2022-03-16

Similar Documents

Publication Publication Date Title
BR112021022404A2 (pt) Composições de oximetazolina e métodos para tratamento de distúrbios oculares
JOP20200011A1 (ar) مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط nlrp
CO2019004137A2 (es) 1,2,4–triazolonas 2,4,5–trisustituidas
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
EA201890641A2 (ru) СТИМУЛЯТОРЫ sGC
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
BR112019009132A2 (pt) composições antimicrobianas sinergísticas
ECSP17026210A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
MX388380B (es) Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
MX2018000412A (es) Moduladores de diaciglicerol aciltransferasa 2 (dgat2).
BR112020016929A8 (pt) Métodos de uso para derivados de benzotriazol trissubstituídos
BR112017012581A2 (pt) tratamento de degeneração da retina com o uso de células progenitoras
BR112017004903A2 (pt) composições para fibras de queratina
MX2021005751A (es) Anticuerpos contra mucina 16 y métodos de uso de los mismos.
MX2022000781A (es) Triterpenoides sintéticos heteroaromáticos sustituidos polarmente en c17, y métodos de uso de los mismos.
BR112018012949A2 (pt) reguladores cftr e métodos de uso dos mesmos
EA201591434A1 (ru) Способ обеспечения глазной нейропротекции
MX378190B (es) Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol.
BR112017009237A2 (pt) composições de éster de forbol e métodos para tratar ou reduzir a duração de citopenia
MX395712B (es) Composición antimicrobiana.
MX417799B (es) Métodos para tratar trastornos mieloproliferativos
CO2018007236A2 (es) Reguladores cftr y métodos de uso
BR112018006474A2 (pt) nova composição oftalmológica compreendendo rebamipide e método para preparar o mesmo
CL2020000586A1 (es) Moduladores de la expresión de enac.

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122024023871-3 PROTOCOLO 870240097827 EM 14/11/2024 16:55.